Chiron Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chiron

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: vinod Khurana who wrote (1)	5/17/1996 1:48:00 PM
From: vinod Khurana	of 23

Ribozyme Pharma Gets Review Exemption From NIH Panel BOULDER, Colo. (Dow Jones)--Ribozyme Pharmaceuticals Inc. (RZYM) said the National Institutes of Health's Recombinant DNA Advisory Committee exempted from review a company-sponsored application for a ribozyme human clinical study. In a press release, Ribozyme Pharmaceuticals said this is its first regulatory filing related to initiation of clinical trials using ribozymes. The proposed study involves transduction of blood progenitor cells from HIV-infected people with a retroviral vector containing two ribozymes. The study is part of a collaboration with Children's Hospital Los Angeles, Chiron Corp. (CHIR), City of Hope National Medical Center and Loma Linda University. The planned clinical trial is a physician-sponsored study measuring the ability of ribozyme-expressing cells to engraft and survive after reinfusion into HIV-1 infected patients. Before human clinical trials can begin, an Investigational New Drug Application must be filed with and approved by the Food and Drug Administration, the company said. V.K

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next